• Chart
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs
    1. Home
    2. Stocks
    3. Sparc Share Price

    Sun Pharma Advanced Research Company Share PriceSun Pharma Advanced Research Company

    Mid Cap 6k Result
    ₹224.85
    2.2 (0.99%)
    As on 26 September, 2023 | 14:54 BSE: 532872 NSE: SPARCISIN: INE232I01014

    Sun Pharma Advanced Research Company Performance

    Day Range

    • Low 222
    • High 231.8
    224.85

    52 Week Range

    • Low 162.1
    • High 265.85
    224.85
    • Open Price223
    • Previous Close222.65
    • Volume1201839

    Start SIP in Sun Pharma Advanced Research Company

    Start SIP

    Sun Pharma Advanced Research Company Share Price

    • Over 1 Month 4.17%
    • Over 3 Month 18.15%
    • Over 6 Month 31.9%
    • Over 1 Year 5.2%

    Sun Pharma Advanced Research Company Key Statistics

    P/E Ratio -31
    PEG Ratio 6.2
    Market Cap Cr 7,297
    Price to Book Ratio 14.2
    EPS -6.9
    Dividend 0
    Relative Strength Index 38.37
    Money Flow Index 59.08
    MACD Signal 2.27
    Average True Range 8.52

    Sun Pharma Advanced Research Company Investment Rating

    • Master Rating:

    • Sun Pharma Advd.Resh. has an operating revenue of Rs. 234.27 Cr. on a trailing 12-month basis. An annual revenue growth of 73% is outstanding, Pre-tax margin of -93% needs improvement, ROE of -43% is poor and needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 50DMA and around 7% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It has recently broken out of a base in its weekly chart but failed to keep its momentum and is trading around -10% from the pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 31 which is a POOR score indicating inconsistency in earnings, a RS Rating of 41 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 113 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Sun Pharma Advanced Research Company Financials
    IndicatorJun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 2448131322825
    Operating Expenses Qtr Cr 1261371159410792
    Operating Profit Qtr Cr -102-9016-63-78-67
    Depreciation Qtr Cr 333333
    Interest Qtr Cr 003322
    Tax Qtr Cr 000000
    Net Profit Qtr Cr -95-8210-68-82-71
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 250144
    Operating Expenses Annual Cr 453324
    Operating Profit Annual in Cr -214-187
    Depreciation Cr 1210
    Interest Annual Cr 813
    Tax Annual Cr 00
    Net Profit Annual Cr -223-203
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr -69-208
    Cash from Investing Activity Annual Cr -548-29
    Cash from Financing Annual Activity Cr 617229
    Net Cash Flow Annual Cr -1-8
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 51331
    Fixed Assets Annual Cr 133118
    Total Non Current Assets Annual Cr 375209
    Total Current Assets Annual Cr 45571
    Total Assets Annual Cr 830280
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 161
    ROE Annual % -43-651
    ROCE Annual % -33-175
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % -85-131
    IndicatorJun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr
    Operating Expenses Qtr Cr
    Operating Profit Qtr Cr
    Depreciation Qtr Cr
    Interest Qtr Cr
    Tax Qtr Cr
    Net Profit Qtr Cr
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr
    Operating Expenses Annual Cr
    Operating Profit Annual in Cr
    Depreciation Cr
    Interest Annual Cr
    Tax Annual Cr
    Net Profit Annual Cr
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr
    Cash from Investing Activity Annual Cr
    Cash from Financing Annual Activity Cr
    Net Cash Flow Annual Cr
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr
    Fixed Assets Annual Cr
    Total Non Current Assets Annual Cr
    Total Current Assets Annual Cr
    Total Assets Annual Cr
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs
    ROE Annual %
    ROCE Annual %
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin %

    Sun Pharma Advanced Research Company Technicals

    EMA & SMA

    Current Price
    ₹224.85
    2.2 (0.99%)
    • Bullish Moving Average
    • ___
    • 5
    • Bearish Moving Average
    • ___
    • 11
    • 20 Day
    • ₹237.01
    • 50 Day
    • ₹231.93
    • 100 Day
    • ₹222.48
    • 200 Day
    • ₹217.73
    • 20 Day
    • ₹242.7
    • 50 Day
    • ₹234.39
    • 100 Day
    • ₹216.29
    • 200 Day
    • ₹207.09

    Sun Pharma Advanced Research Company Resistance and Support

    PIVOT
    ₹224.
    Resistance
    First Resistance ₹226
    Second Resistance ₹229.35
    Third Resistance ₹231.35
    RSI 38.37
    MFI 59.08
    MACD Single Line 2.27
    MACD -1.47
    Support
    First Resistance ₹220.65
    Second Resistance ₹218.65
    Third Resistance ₹215.3

    Sun Pharma Advanced Research Company Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 285,977 10,146,464 35.48
    Week 297,897 10,786,859 36.21
    1 Month 2,028,175 38,717,868 19.09
    6 Month 1,087,232 25,028,078 23.02

    Sun Pharma Advanced Research Company Result Highlights

    Sun Pharma Advanced Research Company Synopsis

    NSE-Medical-Biomed/Biotech

    Sun Pharma Advanced is involved in the business activities of Scientific research and development. Company’s Total Operating Revenue is Rs. 238.78 Cr. and Equity Capital is Rs. 32.45 Cr. for the Year ended 31/03/2023. Sun Pharma Advanced Research Company Ltd. is a Public Limited Listed company incorporated on 01/03/2006 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L73100GJ2006PLC047837 and registration number is 047837.
    Market Cap 7,287
    Sales 234
    Shares in Float 11.03
    No of funds 82
    Yield
    Book Value 14.09
    U/D Vol ratio 3.1
    LTDebt / Equity
    Alpha 0.03
    Beta 0.71

    Sun Pharma Advanced Research Company

    Owner NameJun-23Mar-23Jan-23Dec-22
    Promoters 65.67%65.67%65.67%68.22%
    Mutual Funds 0.21%0.21%0.21%0.25%
    Foreign Portfolio Investors 3.64%3.64%3.54%3.48%
    Financial Institutions/ Banks
    Individual Investors 16.13%16.18%16.34%16%
    Others 14.35%14.3%14.24%12.05%

    Sun Pharma Advanced Research Company Management

    Name Designation
    Mr. Dilip S Shanghvi Chairman & Non-Exe.Director
    Dr. T Rajamannar Non Executive Director
    Dr. Robert J Spiegel Independent Director
    Mr. Sudhir V Valia Non Executive Director
    Ms. Bhavna Doshi Independent Director
    Dr. Ferzaan Engineer Independent Director

    Sun Pharma Advanced Research Company Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Sun Pharma Advanced Research Company Corporate Action

    Date Purpose Remarks
    2023-08-07 Quarterly Results
    2023-05-22 Audited Results & Others To consider Fund Raising
    2023-02-13 Quarterly Results
    2022-11-07 Quarterly Results
    2022-08-08 Quarterly Results & Others Inter alia, to consider and evaluate various options or proposals for raising funds through any of the permissible modes, subject to the receipt of necessary approvals.

    Sun Pharma Advanced Research Company MF Shareholding

    Name Amount(cr)
    Quant Small Cap Fund Growth 8075
    Nippon India Nifty Smallcap 250 Index Fund Reg Gr 657
    Motilal Oswal Nifty 500 Fund Regular Growth 524
    Motilal Oswal Nifty Smallcap 250 Index Fund Regular Growth 422
    SBI Nifty Smallcap 250 Index Fund Regular Growth 281
    • Company Name
    • CMP
    • Chg(%)
    • Company Name
    • CMP
    • Chg(%)

    Sun Pharma Advanced Research Company FAQs

    What is Share Price of Sun Pharma Advanced Research Company ?

    Sun Pharma Advanced Research Company share price is ₹224 As on 26 September, 2023 | 14:40

    What is the Market Cap of Sun Pharma Advanced Research Company ?

    The Market Cap of Sun Pharma Advanced Research Company is ₹7296.9 Cr As on 26 September, 2023 | 14:40

    What is the P/E ratio of Sun Pharma Advanced Research Company ?

    The P/E ratio of Sun Pharma Advanced Research Company is -31 As on 26 September, 2023 | 14:40

    What is the PB ratio of Sun Pharma Advanced Research Company ?

    The PB ratio of Sun Pharma Advanced Research Company is 14.2 As on 26 September, 2023 | 14:40

    Q2FY23

    More Information

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI REGN No.: ARN-104096 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support desk helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
    ©2023, 5Paisa Capital Ltd. All Rights Reserved.
    We are ISO 27001:2013 Certified.